180 Wealth Advisors LLC Has $2.77 Million Holdings in Pfizer Inc. (PFE)

180 Wealth Advisors LLC cut its stake in Pfizer Inc. (NYSE:PFE) by 1.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 62,933 shares of the biopharmaceutical company’s stock after selling 761 shares during the quarter. Pfizer makes up approximately 1.3% of 180 Wealth Advisors LLC’s portfolio, making the stock its 10th largest holding. 180 Wealth Advisors LLC’s holdings in Pfizer were worth $2,773,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Advocacy Wealth Management Services LLC increased its holdings in shares of Pfizer by 48.2% during the 4th quarter. Advocacy Wealth Management Services LLC now owns 793 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 258 shares during the last quarter. Contravisory Investment Management Inc. increased its holdings in shares of Pfizer by 182.6% during the 4th quarter. Contravisory Investment Management Inc. now owns 1,153 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 745 shares during the last quarter. Vestor Capital LLC acquired a new stake in shares of Pfizer during the 3rd quarter worth approximately $53,000. Arlington Partners LLC increased its holdings in shares of Pfizer by 64.7% during the 4th quarter. Arlington Partners LLC now owns 2,141 shares of the biopharmaceutical company’s stock worth $93,000 after buying an additional 841 shares during the last quarter. Finally, Highwater Wealth Management LLC acquired a new stake in shares of Pfizer during the 4th quarter worth approximately $123,000. Institutional investors own 69.49% of the company’s stock.

In other news, insider Alexander R. Mackenzie sold 15,000 shares of Pfizer stock in a transaction on Monday, April 1st. The shares were sold at an average price of $42.83, for a total transaction of $642,450.00. Following the completion of the sale, the insider now directly owns 124,994 shares of the company’s stock, valued at approximately $5,353,493.02. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Mikael Dolsten sold 149,553 shares of Pfizer stock in a transaction on Monday, March 4th. The stock was sold at an average price of $43.55, for a total transaction of $6,513,033.15. Following the sale, the insider now directly owns 390,097 shares of the company’s stock, valued at $16,988,724.35. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 332,526 shares of company stock valued at $14,346,539. Corporate insiders own 0.09% of the company’s stock.

Several research firms recently weighed in on PFE. Credit Suisse Group set a $45.00 target price on shares of Pfizer and gave the company a “neutral” rating in a report on Tuesday, January 1st. Cantor Fitzgerald set a $53.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Sunday, December 30th. Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, April 3rd. Bank of America lifted their target price on shares of Pfizer from $45.00 to $48.00 and gave the company a “buy” rating in a report on Monday, April 1st. Finally, Citigroup reiterated a “neutral” rating and issued a $41.00 target price on shares of Pfizer in a report on Wednesday, February 20th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and seven have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $45.61.

PFE stock traded up $0.24 during midday trading on Thursday, hitting $39.61. The company’s stock had a trading volume of 16,924,903 shares, compared to its average volume of 24,567,809. The stock has a market capitalization of $234.57 billion, a PE ratio of 13.20, a P/E/G ratio of 2.38 and a beta of 0.75. Pfizer Inc. has a 52-week low of $34.37 and a 52-week high of $46.47. The company has a quick ratio of 1.33, a current ratio of 1.57 and a debt-to-equity ratio of 0.52.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 29th. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.01. The business had revenue of $13.98 billion during the quarter, compared to analysts’ expectations of $13.92 billion. Pfizer had a net margin of 20.79% and a return on equity of 26.02%. The company’s revenue for the quarter was up 2.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.62 EPS. Analysts expect that Pfizer Inc. will post 2.86 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 10th will be given a dividend of $0.36 per share. This represents a $1.44 annualized dividend and a dividend yield of 3.64%. Pfizer’s dividend payout ratio (DPR) is currently 48.00%.

WARNING: “180 Wealth Advisors LLC Has $2.77 Million Holdings in Pfizer Inc. (PFE)” was first published by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://www.baseballdailydigest.com/news/2019/04/25/pfizer-inc-pfe-is-180-wealth-advisors-llcs-10th-largest-position.html.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: Cost of Debt

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.